(SA16) Buprenorphine and Methadone in PALTC: What Every Medical Practitioner Needs to Know

Saturday, March 9, 2024

2:15 PM - 3:45 PM CT

Room: Stars at Night Ballroom B1

CME: (1.5) MOC: (1.5) CMD Clinical: (1.5) NP Pharmacology Hours (.75)

Session Chair/Speaker(s)

Sabine M. von Preyss-Friedman, MD, CMD, FACP (she/her/hers)

CMO
Avalon Healthcare Inc, Caldera Care
Seattle, Washington

Disclosure(s): No relevant financial relationships.

Speaker(s)

Swati Gaur, MD, MBA, CMD, AGSF (she/her/hers)

Medical Director
Northeast Georgia Health System
Alpharetta, GA

Disclosure(s): No financial relationships to disclose.
JA

Jennifer Azen, MD, MPH (she/her/hers)

Associate Clinical Professor of Medicine, General Internal Medicine
University of Washington
Seattle, WA

Disclosure(s): No relevant financial relationships.
Jacob Berelowitz, LNHA, LMSW, CPHQ, CCM (he/him/his)

Program Manager
Center of Excellence for Behavioral Health in Nursing Facilities (COE-NF)
Atlanta, GA

Disclosure(s): No financial relationships to disclose.

Disclosure(s):

Sabine M. von Preyss-Friedma, MD CMD FACP: No relevant financial relationships.

Swati Gaur, MD, MBA, CMD, AGSF: No financial relationships to disclose.

Jennifer Azen, MD, MPH: No relevant financial relationships.

Jacob Berelowitz, LNHA, LMSW, CPHQ, CCM: No financial relationships to disclose.

This presentation will include diagnostic guidelines for Opioid use disorder and an in-depth review of medications that are FDA approved for substance use disorder (Methadone, Buprenorphine and Naltrexone). Special consideration will be given to co-treatment of acute pain in patients with substance use disorder in PALTC and safely transitioning patients with SUD back to the community. A model of collaboration with a Methadone clinic will be introduced and the perspective of the Skilled Nursing Facility staff will be highlighted. Opportunities for treatment of chronic pain in palliative and other settings with Methadone and buprenorphine will also be discussed. This session presented by an interdisciplinary panel will include case presentations from the “real PALTC world” with audience interaction.

Learning Objectives:

At the completion of this session, learners will be able to:

Diagnose substance use disorder (SUD)
Continue to safely prescribe Buprenorphine as treatment for substance use disorder in the PALTC setting
Plan effective collaboration with a Methadone treatment clinic to co-treat patients on Methadone for the treatment of SUD
Utilize Buprenorphine and Methadone as alternative agents for treatment of chronic pain